Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting.

Cartwright TH, Parisi M, Espirito JL, Wilson TW, Pelletier C, Patel M, Babiker HM.

Drugs Real World Outcomes. 2018 Sep;5(3):149-159. doi: 10.1007/s40801-018-0137-x.

2.

Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey.

Monk BJ, Lammers PE, Cartwright T, Jacobs I.

Pharmaceuticals (Basel). 2017 Jan 28;10(1). pii: E19. doi: 10.3390/ph10010019.

3.

Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.

Ma WW, Saif MW, El-Rayes BF, Fakih MG, Cartwright TH, Posey JA, King TR, von Borstel RW, Bamat MK.

Cancer. 2017 Jan 1;123(2):345-356. doi: 10.1002/cncr.30321. Epub 2016 Sep 13.

4.

Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.

Tanvetyanon T, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Malafa M, Jacobsen PB.

J Oncol Pract. 2015 Jul;11(4):332-7. doi: 10.1200/JOP.2014.001750. Epub 2015 May 19.

PMID:
25991639
5.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators.

Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262.

PMID:
25877855
6.

Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.

Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D.

Lancet Oncol. 2014 Dec;15(13):1481-1492. doi: 10.1016/S1470-2045(14)70486-3. Epub 2014 Nov 12.

7.

Florida Initiative for Quality Cancer Care: Changes in Psychosocial Quality of Care Indicators Over a 3-Year Interval.

Jacobsen PB, Lee JH, Fulp W, Siegel EM, Shibata D, Laronga C, Gray J, Tanvetyanon T, Schreiber F, Brown R, Levine R, Cartwright T, Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Malafa M.

J Oncol Pract. 2015 Jan;11(1):e103-9. doi: 10.1200/JOP.2014.001525. Epub 2014 Oct 28.

8.

Florida Initiative for Quality Cancer Care: improvements in breast cancer quality indicators during a 3-year interval.

Laronga C, Gray JE, Siegel EM, Lee JH, Fulp WJ, Fletcher M, Schreiber F, Brown R, Levine R, Cartwright T, Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Shibata D, Malafa M, Jacobsen PB.

J Am Coll Surg. 2014 Oct;219(4):638-45.e1. doi: 10.1016/j.jamcollsurg.2014.03.063. Epub 2014 Jul 1.

9.

Changes in the care of non-small-cell lung cancer after audit and feedback: the Florida initiative for quality cancer care.

Tanvetyanon T, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G Jr, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Malafa M, Jacobsen PB.

J Oncol Pract. 2014 Jul;10(4):e247-54. doi: 10.1200/JOP.2013.001275. Epub 2014 Apr 15.

PMID:
24737876
10.

Florida Initiative for Quality Cancer Care: improvements on colorectal cancer quality of care indicators during a 3-year interval.

Siegel EM, Jacobsen PB, Lee JH, Malafa M, Fulp W, Fletcher M, Smith JC, Brown R, Levine R, Cartwright T, Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Shibata D.

J Am Coll Surg. 2014 Jan;218(1):16-25.e1-4. doi: 10.1016/j.jamcollsurg.2013.09.008. Epub 2013 Nov 23.

11.

Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.

Infante JR, Reid TR, Cohn AL, Edenfield WJ, Cescon TP, Hamm JT, Malik IA, Rado TA, McGee PJ, Richards DA, Tarazi J, Rosbrook B, Kim S, Cartwright TH.

Cancer. 2013 Jul 15;119(14):2555-63. doi: 10.1002/cncr.28112. Epub 2013 Apr 19.

12.

Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.

Cartwright TH.

Clin Colorectal Cancer. 2013 Jun;12(2):86-94. doi: 10.1016/j.clcc.2012.12.001. Epub 2013 Apr 2. Review.

PMID:
23562587
13.

Implementation of a performance improvement initiative in colorectal cancer care.

Marshall JL, Cartwright TH, Berry CA, Stowell SA, Miller SC.

J Oncol Pract. 2012 Sep;8(5):309-14. doi: 10.1200/JOP.2011.000461. Epub 2012 May 15.

14.

Evaluating the quality of colorectal cancer care in the state of Florida: results from the Florida Initiative for Quality Cancer Care.

Siegel EM, Jacobsen PB, Malafa M, Fulp W, Fletcher M, Lee JH, Smith JC, Brown R, Levine R, Cartwright T, Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Shibata D.

J Oncol Pract. 2012 Jul;8(4):239-45. doi: 10.1200/JOP.2011.000477. Epub 2012 Jun 12.

15.

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM.

Lancet Oncol. 2012 Dec;13(12):1225-33. doi: 10.1016/S1470-2045(12)70509-0. Epub 2012 Nov 16.

PMID:
23168362
16.

Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology.

Cartwright TH, Yim YM, Yu E, Chung H, Halm M, Forsyth M.

Clin Colorectal Cancer. 2012 Dec;11(4):238-46. doi: 10.1016/j.clcc.2012.05.005. Epub 2012 Jun 2.

PMID:
22658457
17.

A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Hurwitz H, Mitchell EP, Cartwright T, Kwok A, Hu S, McKenna E, Patt YZ.

Oncologist. 2012;17(7):937-46. doi: 10.1634/theoncologist.2012-0071. Epub 2012 May 23.

18.

Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial.

Jacobsen PB, Wells KJ, Meade CD, Quinn GP, Lee JH, Fulp WJ, Gray JE, Baz RC, Springett GM, Levine RM, Markham MJ, Schreiber FJ, Cartwright TH, Burke JM, Siegel RD, Malafa MP, Sullivan D.

J Clin Oncol. 2012 Jul 10;30(20):2516-21. doi: 10.1200/JCO.2011.39.5186. Epub 2012 May 21.

19.

Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida.

Tanvetyanon T, Corman M, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Bepler G, Siegel E, Shibata D, Malafa M, Jacobsen PB.

J Oncol Pract. 2011 Nov;7(6):e25-31.

20.

Treatment decisions after diagnosis of metastatic colorectal cancer.

Cartwright TH.

Clin Colorectal Cancer. 2012 Sep;11(3):155-66. doi: 10.1016/j.clcc.2011.11.001. Epub 2011 Dec 21. Review.

PMID:
22192364

Supplemental Content

Loading ...
Support Center